Opinion|Videos|April 1, 2024
HCC Treatment Strategy Driven by Real-World Evidence
Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
5